FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma

NEXT STORY
Roche’s faricimab meets primary endpoint in two global phase III studies and shows potential to extend time between treatments up to 16 weeks for people with neovascular age-related macular degeneration
PREV STORY
First US Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Global Vaccine Market to Reach US$ 57 Billion by 2025, Fostered by Sudden Outbreak of COVID-19, By IMARC Group

author_avatar
NASDAQ Market News

Samsung Bioepis Announces Five-year Follow-up Results for ONTRUZANT® (trastuzumab) in Early or Locally Advanced HER2 Positive Breast Cancer at the European Society for Medical Oncology (ESMO) Virtual Congress 2021

author_avatar
NASDAQ Market News

Avalo Therapeutics Appoints Stephen Smolinski as Chief Commercial Officer

author_avatar
NASDAQ Market News